Anti-Angiogenics: Their Value in Lung Cancer Therapy

Melanie Janning; Sonja Loges

doi:10.1159/000488119

Anti-Angiogenics: Their Value in Lung Cancer Therapy

Standard

Anti-Angiogenics: Their Value in Lung Cancer Therapy. / Janning, Melanie ; Loges, Sonja.

In: ONCOL RES TREAT, Vol. 41, No. 4, 2018, p. 172-180.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Janning, M & Loges, S 2018, 'Anti-Angiogenics: Their Value in Lung Cancer Therapy', ONCOL RES TREAT, vol. 41, no. 4, pp. 172-180. https://doi.org/10.1159/000488119

APA

Janning, M., & Loges, S. (2018). Anti-Angiogenics: Their Value in Lung Cancer Therapy. ONCOL RES TREAT, 41(4), 172-180. https://doi.org/10.1159/000488119

Vancouver

Janning M , Loges S. Anti-Angiogenics: Their Value in Lung Cancer Therapy. ONCOL RES TREAT. 2018;41(4):172-180. https://doi.org/10.1159/000488119

Bibtex

@article{7edad55eab904eefa02e22cc847b95fe,

title = "Anti-Angiogenics: Their Value in Lung Cancer Therapy",

abstract = "Lung cancer is the second most common cancer and the leading cause of cancer-related deaths. Different targeted therapies and the introduction of immunotherapy have successfully improved outcome for patients with non-small lung cancer (NSCLC). Anti-angiogenic drugs are an essential component in the treatment of NSCLC patients. The vascular endothelial growth factor (VEGF)-A antibody bevacizumab is approved for first-line treatment of advanced-stage patients in combination with platinum-based chemotherapy. Ramucirumab, a VEGF receptor antibody, and nintedanib, an anti-angiogenic multi-tyrosine kinase inhibitor, are approved for second-line treatment in combination with docetaxel. This review provides a summary of pivotal trials with anti-angiogenic drugs in NSCLC in different settings. We give an overview of how to position anti-angiogenic therapy in the current treatment algorithms and highlight future directions. The identification of predictive biomarkers for patient selection could improve the success of anti-angiogenic drugs and represents an important area of research. In addition, novel therapeutic targets including endothelial metabolomic intermediates and cellular components of the tumor microenvironment could lead to the identification of innovative new targets besides the VEGF axis.",

keywords = "Journal Article",

author = "Melanie Janning and Sonja Loges",

note = "{\textcopyright} 2018 S. Karger GmbH, Freiburg.",

year = "2018",

doi = "10.1159/000488119",

language = "English",

volume = "41",

pages = "172--180",

journal = "ONCOL RES TREAT",

issn = "2296-5270",

publisher = "S. Karger AG",

number = "4",

}

RIS

TY - JOUR

T1 - Anti-Angiogenics: Their Value in Lung Cancer Therapy

AU - Janning, Melanie

AU - Loges, Sonja

PY - 2018

Y1 - 2018

N2 - Lung cancer is the second most common cancer and the leading cause of cancer-related deaths. Different targeted therapies and the introduction of immunotherapy have successfully improved outcome for patients with non-small lung cancer (NSCLC). Anti-angiogenic drugs are an essential component in the treatment of NSCLC patients. The vascular endothelial growth factor (VEGF)-A antibody bevacizumab is approved for first-line treatment of advanced-stage patients in combination with platinum-based chemotherapy. Ramucirumab, a VEGF receptor antibody, and nintedanib, an anti-angiogenic multi-tyrosine kinase inhibitor, are approved for second-line treatment in combination with docetaxel. This review provides a summary of pivotal trials with anti-angiogenic drugs in NSCLC in different settings. We give an overview of how to position anti-angiogenic therapy in the current treatment algorithms and highlight future directions. The identification of predictive biomarkers for patient selection could improve the success of anti-angiogenic drugs and represents an important area of research. In addition, novel therapeutic targets including endothelial metabolomic intermediates and cellular components of the tumor microenvironment could lead to the identification of innovative new targets besides the VEGF axis.

AB - Lung cancer is the second most common cancer and the leading cause of cancer-related deaths. Different targeted therapies and the introduction of immunotherapy have successfully improved outcome for patients with non-small lung cancer (NSCLC). Anti-angiogenic drugs are an essential component in the treatment of NSCLC patients. The vascular endothelial growth factor (VEGF)-A antibody bevacizumab is approved for first-line treatment of advanced-stage patients in combination with platinum-based chemotherapy. Ramucirumab, a VEGF receptor antibody, and nintedanib, an anti-angiogenic multi-tyrosine kinase inhibitor, are approved for second-line treatment in combination with docetaxel. This review provides a summary of pivotal trials with anti-angiogenic drugs in NSCLC in different settings. We give an overview of how to position anti-angiogenic therapy in the current treatment algorithms and highlight future directions. The identification of predictive biomarkers for patient selection could improve the success of anti-angiogenic drugs and represents an important area of research. In addition, novel therapeutic targets including endothelial metabolomic intermediates and cellular components of the tumor microenvironment could lead to the identification of innovative new targets besides the VEGF axis.

KW - Journal Article

U2 - 10.1159/000488119

DO - 10.1159/000488119

M3 - SCORING: Review article

C2 - 29631257

VL - 41

SP - 172

EP - 180

JO - ONCOL RES TREAT

JF - ONCOL RES TREAT

SN - 2296-5270

IS - 4

ER -